Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15994489 | 0.80 | LMNA (0.33) | — | |
| SCHEMBL11003030 | 0.80 | CHRM5 (0.36) | CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL15526739 | 0.78 | LMNA (0.32) | — | |
| Hydrochloric Acid SCHEMBL15526661 | 0.77 | LMNA (0.35) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL15526993 | 0.75 | CHRM2 (0.31) | CHRM5CHRM3 | |
| SCHEMBL1819138 | 0.71 | CHRM2 (0.34) | CHRM5CHRM3MEN1KMT2A | |
| SCHEMBL361322 | 0.70 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL16495279 | 0.70 | ADRB1 (0.43) | MEN1KMT2A | |
| SCHEMBL930621 | 0.69 | MEN1 (0.34) | CHRM5CHRM3MEN1KMT2A | |
| SCHEMBL27862956 | 0.67 | CYP2D6 (0.35) | CHRM3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101511798-B | [4,5'] bipyrimidinyl-6, 4' -diamine derivatives as protein kinase inhibitors | IRM LLC | 2011-11-02 | — | — | CN | claimed |
| US-8026243-B2 | [4,5′]Bipyrimidinyl-6,4′-diamine derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | claimed |
| EP-2044036-B1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2011-05-04 | — | — | EP | claimed |
| US-20100234376-A1 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors | NOVARTIS AG | 2010-09-16 | — | — | US | claimed |
| EP-2044036-A1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | claimed |
| WO-2008008747-A1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2008-01-17 | — | — | WO | claimed |
| CN-101511798-B | [4,5'] bipyrimidinyl-6, 4' -diamine derivatives as protein kinase inhibitors | IRM LLC | 2011-11-02 | — | — | CN | disclosed |
| US-8026243-B2 | [4,5′]Bipyrimidinyl-6,4′-diamine derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | disclosed |
| EP-2044036-B1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2011-05-04 | — | — | EP | disclosed |
| US-20100234376-A1 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors | NOVARTIS AG | 2010-09-16 | — | — | US | disclosed |
| EP-2044036-A1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008747-A1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234376-A1 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors | FGFR3, ERBB2, ERBB4 | CHRM5 4553/4885CHRM3 4497/4885MEN1 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.